Meta-analyses of placebo-controlled trials of acamprosate for the treatment of alcohol dependence: Impact of the combined pharmacotherapies and behavior interventions study

Journal of Addiction Medicine

Volumn 3, Issue 2, 2009, Pages 74-82

  Dranitsaris, George ^a,b,c   Selby, Peter ^a,b   Negrete, Juan Carlos ^a,b  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c NONE   (Canada)

Author keywords

Acamprosate; Alcohol dependence; Meta analysis; Naltrexone

Indexed keywords

EID: 70349240611     PISSN: 19320620     EISSN: 19353227     Source Type: Journal    
DOI: 10.1097/ADM.0b013e318182d890     Document Type: Article

References (42)

1. National Institute on Alcohol Abuse and Alcoholism. Tenth special report to U.S. Congress on alcohol and health, 2000. Washington, DC: US Department of Health and Human Services; 2000.
2. Yi H, Williams GD, Dufour MC. Surveillance report #56: Trends in alcohol related fatal traffic crashes. United States, 1977-1999. Rockville, MD: National Institute on Alcohol Abuse and Alcoholism, Division of Biometry and Epidemiology; 2001.
3. Holland P, Mushinski M. Costs of alcohol and drug abuse in the United States, 1992. Alcohol/Drugs COI Study Team. Stat Bull Metrop Insur Co. 1999;80:2-9.
4. Single E, Robson L, Xie X, et al. The economic costs of alcohol, tobacco and illicit drugs in Canada, 1992. Addiction. 1998;93:991-1006. (Pubitemid 28320991)
5. Whitlock EP, Polen MR, Green CA, et al. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140:557-568
6. Kienast T, Heinz A. Therapy and supportive care of alcoholics: Guidelines for practitioners. Dig Dis. 2005;23:304-309.
7. Pettinati HM, Rabinowitz AR. Choosing the right medication for the treatment of alcoholism. Curr Psychiatry Rep. 2006;8:383-388.
8. Saivin S, Hulot T, Chabac S, et al. Clinical pharmacokinetics of acamprosate. Clin Pharmacokinet. 1998;35:331-345.
9. Mason BJ. Acamprosate in the treatment of alcohol dependence. Expert Opin Pharmacother. 2005;6:2103-2115.
10. Srisurapanont M, Jarusuraisin N. Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials. Int J Neuropsy- chopharmacol. 2005;8:267-280.
11. Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res. 2004;28:51-63.
12. Srisurapanont M. Review: naltrexone reduces alcohol consumption (in short term) in patients with alcohol dependence. Evid Based Med. 2005;10:120.
13. Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003-2017.
14. Jonas JM, Chabac S. Pharmacotherapy and behaviour intervention for alcohol dependence. JAMA. 2006;296:1727-1729.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association; 1994.
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
17. Higgins JPT, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta analyses. BMJ. 2003;327:557-560.
18. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50:1088-1101.
19. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-634.
20. Lau J, Antman EM, Jimenez-Silva J, et al. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992;327: 248-254.
21. Rubio G, Jimenez-Arriero MA, Ponce G, et al. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol. 2001;36:419-425.
22. Morley KC, Teesson M, Reid SC, et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction. 2006;101:1451-1462.
23. Kiefer F, Andersohn F, Otte F, et al. Long term effects of pharmacotherapy on relapse prevention in alcohol dependence. Acta Neuropsy- chiatrica. 2004;16:233-238.
24. Harbour R, Miller J. A new system for grading recommendations in evidence based guidelines. BMJ. 2001;323:334-336.
25. Guyatt GH, Sackett DL, Cook DJ. Users' guides to the medical literature: how to use an article about therapy or prevention. JAMA. 1994; 271:59-63.
26. Fahey T, Griffiths S, Peters TJ. Evidence based purchasing: understanding results of clinical trials and systematic reviews. BMJ. 1995;311: 1056-1059.
27. Mason BJ, Goodman AM, Chabac S, et al. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res. 2006;40:383-393.
28. Heilig M, Egli M. Pharmacological treatment of alcohol dependence: target symptoms and target mechanisms. Pharmacol Ther. 2006;111: 855-876.
29. Rist F, Randall CL, Heather N, et al. New developments in alcoholism treatment research in Europe. Alcohol Clin Exp Res. 2005;291127-291132.
30. Besson J, Aeby F, Kasas A, et al. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res. 1998;22:573-579.
31. Chick J, Howlett H, Morgan MY, et al. United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acam- prosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. 2000;35:176-187.
32. Geerlings PJ, Ansoms C, Van den Brink W. Acamprosate and prevention of relapse in alcoholics. Results of a randomized, placebo-controlled, double-blind study in out-patient alcoholics in the Netherlands, Belgium and Luxembourg. Eur Addict Res. 1997;3:129-137.
33. Gual A, Lehert P. Acamprosate during and after acute alcohol withdrawal: a double blind placebo controlled study in Spain. Alcohol Alcohol. 2001;413-418.
34. Ladewig D, Knecht T, Lehert P. Acamprosate-a stabilizing factor in long-term withdrawal of alcoholic patients. Ther Umsch. 1993;50:182-188.
35. Paille FM, Guelfi JD, Perkins AC, et al. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. 1993;30:239-247.
36. Pelc I, Verbanck P, Le Bon O, et al. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br J Psychiatry. 1997;171: 73-77.
37. Poldrugo F. Acamprosate treatment in a long-term community-based alcohol rehabilitation program. Addiction. 1997;92:1537-1546.
38. Sass H, Soyka M, Mann K, et al. Relapse prevention by acamprosate. Results from a placebo controlled study on alcohol dependence. Arch Gen Psychiatry. 1996;53:673-680.
39. Tempesta E, Janiri L, Bignamini A, et al. Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol. 2000;35:202-209.
40. Whitworth AB, Fischer F, Lesch OM, et al. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet. 1996;347:1438-1442.
41. Baltieri DA, De Andrade AG. Acamprosate in alcohol dependence: a randomized controlled efficacy study in a standard clinical setting. J Stud Alcohol. 2004;65:136-139.
42. Namkoong K, Lee BO, Lee PG, et al. Acamprosate in Korean alcohol- dependent patients: a multi-centre, randomized, double-blind, placebo- controlled study. Alcohol. 2003;38:135-141.